Experience with ceftazidime in obstetrics and gynaecology in Japan.
The effects of ceftazidime were evaluated in 238 patients. Among these patients 221 (93%) were assessed as having either 'excellent' or 'good' clinical responses. Bacteriologically, in 102 (87%) out of 117 cases, the causative organisms were either eliminated or replaced. Adverse events noted were limited to mild rashes in 2 patients and gastric discomfort in another. Penetration of ceftazidime into uterine tissues was studied and, following an intravenous bolus dose of 1 g, concentrations in various parts of the uterus averaged 36 to 57 mg/kg at 11 to 26 min. Concentrations in intrapelvic fluid in patients undergoing radical hysterectomy averaged 37 mg/l at 30 min after an intravenous bolus injection of 1 g, and 23 mg/l at 30 min after completion of a 60-min infusion.
D001424:Bacterial Infections / Q000188:drug therapy*; D001826:Body Fluids / Q000378:metabolism; D002442:Ceftazidime; D002511:Cephalosporins / Q000378:metabolism / Q000627:therapeutic use*; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D007564:Japan; D014018:Tissue Distribution; D014599:Uterus / Q000378:metabolism
D002511:Cephalosporins; D002442:Ceftazidime